Your browser doesn't support javascript.
Correlates of breakthrough Omicron (B.1.1.529) infections in a prospective cohort of vaccinated patients with rheumatic diseases.
Benny, Libin; Mehta, Pankti; Ahmed, Sakir; Paul, Aby; Sukumaran, Aswathy; Mohanan, Manju; Vijayan, Anuroopa; Kaveri, K; Padmaja, R; Shenoy, Padmanabha.
  • Benny L; Centre for Arthritis and Rheumatism Excellence, Dr Shenoys Care, Nettor, Kochi, 682040, Kerala, India.
  • Mehta P; King George's Medical University, Lucknow, Uttar Pradesh, India.
  • Ahmed S; Clinical Immunology and Rheumatology, Kalinga Institute of Medical Sciences, Bhubaneswar, Odisha, India.
  • Paul A; Centre for Arthritis and Rheumatism Excellence, Dr Shenoys Care, Nettor, Kochi, 682040, Kerala, India.
  • Sukumaran A; Centre for Arthritis and Rheumatism Excellence, Dr Shenoys Care, Nettor, Kochi, 682040, Kerala, India.
  • Mohanan M; Centre for Arthritis and Rheumatism Excellence, Dr Shenoys Care, Nettor, Kochi, 682040, Kerala, India.
  • Vijayan A; Centre for Arthritis and Rheumatism Excellence, Dr Shenoys Care, Nettor, Kochi, 682040, Kerala, India.
  • Kaveri K; Centre for Arthritis and Rheumatism Excellence, Dr Shenoys Care, Nettor, Kochi, 682040, Kerala, India.
  • Padmaja R; Centre for Arthritis and Rheumatism Excellence, Dr Shenoys Care, Nettor, Kochi, 682040, Kerala, India.
  • Shenoy P; Centre for Arthritis and Rheumatism Excellence, Dr Shenoys Care, Nettor, Kochi, 682040, Kerala, India. drdpshenoy@gmail.com.
Rheumatol Int ; 43(6): 1033-1039, 2023 06.
Article in English | MEDLINE | ID: covidwho-2292161
ABSTRACT

BACKGROUND:

Data on the effectiveness of SARS-CoV-2 vaccines and the durability of protection against the prevalent Omicron variant are scarce, especially in patients with autoimmune rheumatic diseases (AIRDs). Hence, we prospectively studied Omicron breakthrough infections in patients with AIRDs and attempted to isolate associated risk factors.

METHODS:

Patients with AIRDs who had completed primary vaccination with either AZD1222 or BBV152 vaccines were included and prospectively followed up from January 2022 onwards for the development of breakthrough Omicron infections. The time interval from the last event [2nd dose of vaccination (V) or past COVID-19 infection (I) whichever was later] to Omicron infection was recorded. Patients were divided based on the events and their order of occurrence into V + V, V + I, I + V, V + I + V, and V + V + I groups. The incidence of breakthrough infections and their predictors were studied with a focus on the vaccine type and hybrid (H) immunity (vaccinated individuals with a history of COVID-19 infection).

RESULTS:

We included 907 patients with AIRDs (53.5 ± 11.7 years and a male-to-female ratio of 15.1), and the majority of patients had received AZD1222 (755, 83.2%). Breakthrough infections were observed in 158 of 907(17.4%) of which 97 (10.4%) were confirmed by RT-PCR. Breakthrough infections were significantly greater in the V versus the H group (15.7% and 3.5%, log-rank test, p = < 0.01). Among the hybrid group, the order of infection and vaccination had no bearing on the risk of breakthrough infections. On multivariate analysis, breakthrough infections were significantly lesser in the H versus the V group [HR 0.2(0.1-0.4); p = 0.01].

CONCLUSION:

The risk of breakthrough Omicron infections in fully vaccinated patients with AIRDs was 17.4% with a significantly lower risk in patients with hybrid immunity.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Autoimmune Diseases / Rheumatic Diseases / COVID-19 Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines / Variants Limits: Female / Humans / Male Language: English Journal: Rheumatol Int Year: 2023 Document Type: Article Affiliation country: S00296-023-05314-5

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Autoimmune Diseases / Rheumatic Diseases / COVID-19 Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines / Variants Limits: Female / Humans / Male Language: English Journal: Rheumatol Int Year: 2023 Document Type: Article Affiliation country: S00296-023-05314-5